Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 30, 2004

Conditions
Prevention of Meningococcal Infection
Interventions
BIOLOGICAL

Meningococcal C Conjugate Vaccine

Trial Locations (1)

20122

Istituto di Pediatria, Università degli Studi di Milano, Milan

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY